SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

NASDAQ:SNDX • US87164F1057

20.63 USD
+0.38 (+1.88%)
At close: Feb 19, 2026
20.63 USD
0 (0%)
After Hours: 2/19/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall SNDX gets a fundamental rating of 3 out of 10. We evaluated SNDX against 521 industry peers in the Biotechnology industry. SNDX has a bad profitability rating. Also its financial health evaluation is rather negative. SNDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SNDX had negative earnings in the past year.
  • SNDX had a negative operating cash flow in the past year.
  • SNDX had negative earnings in 4 of the past 5 years.
  • SNDX had negative operating cash flow in 4 of the past 5 years.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -56.44%, SNDX perfoms like the industry average, outperforming 44.53% of the companies in the same industry.
  • The Return On Equity of SNDX (-269.78%) is worse than 71.59% of its industry peers.
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROIC N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 95.44%, SNDX belongs to the top of the industry, outperforming 95.59% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for SNDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SNDX has been increased compared to 1 year ago.
  • Compared to 5 years ago, SNDX has more shares outstanding
  • Compared to 1 year ago, SNDX has a worse debt to assets ratio.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • SNDX has an Altman-Z score of -1.96. This is a bad value and indicates that SNDX is not financially healthy and even has some risk of bankruptcy.
  • SNDX has a Altman-Z score (-1.96) which is comparable to the rest of the industry.
  • SNDX has a Debt/Equity ratio of 2.78. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.78, SNDX is not doing good in the industry: 79.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Altman-Z -1.96
ROIC/WACCN/A
WACC8.46%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 4.64 indicates that SNDX has no problem at all paying its short term obligations.
  • SNDX has a Current ratio (4.64) which is in line with its industry peers.
  • SNDX has a Quick Ratio of 4.42. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
  • SNDX's Quick ratio of 4.42 is in line compared to the rest of the industry. SNDX outperforms 52.40% of its industry peers.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.42
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • SNDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.55%.
  • The Revenue has grown by 597.19% in the past year. This is a very strong growth!
  • The Revenue has been growing by 73.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%

3.2 Future

  • Based on estimates for the next years, SNDX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.70% on average per year.
  • SNDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.20% yearly.
EPS Next Y14.45%
EPS Next 2Y25.36%
EPS Next 3Y24.99%
EPS Next 5Y21.7%
Revenue Next Year72.51%
Revenue Next 2Y92.9%
Revenue Next 3Y78.62%
Revenue Next 5Y58.2%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
  • Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SNDX's earnings are expected to grow with 24.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.36%
EPS Next 3Y24.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (2/19/2026, 8:00:02 PM)

After market: 20.63 0 (0%)

20.63

+0.38 (+1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-09
Inst Owners120.09%
Inst Owner Change-0.83%
Ins Owners1.12%
Ins Owner Change10.19%
Market Cap1.79B
Revenue(TTM)111.55M
Net Income(TTM)-311.41M
Analysts87
Price Target40.09 (94.33%)
Short Float %24.77%
Short Ratio15.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.08%
Min EPS beat(2)4.24%
Max EPS beat(2)19.92%
EPS beat(4)3
Avg EPS beat(4)-79.67%
Min EPS beat(4)-370.62%
Max EPS beat(4)27.8%
EPS beat(8)7
Avg EPS beat(8)-34.32%
EPS beat(12)11
Avg EPS beat(12)-20.09%
EPS beat(16)15
Avg EPS beat(16)19.64%
Revenue beat(2)1
Avg Revenue beat(2)16.23%
Min Revenue beat(2)-6.26%
Max Revenue beat(2)38.73%
Revenue beat(4)2
Avg Revenue beat(4)-5.66%
Min Revenue beat(4)-91.24%
Max Revenue beat(4)38.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.99%
EPS NQ rev (1m)-0.77%
EPS NQ rev (3m)2.18%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)-0.38%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-2.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.07
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS1.28
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.44%
FCFM N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.42
Altman-Z -1.96
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y14.45%
EPS Next 2Y25.36%
EPS Next 3Y24.99%
EPS Next 5Y21.7%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%
Revenue Next Year72.51%
Revenue Next 2Y92.9%
Revenue Next 3Y78.62%
Revenue Next 5Y58.2%
EBIT growth 1Y4.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.98%
EBIT Next 3Y23.94%
EBIT Next 5YN/A
FCF growth 1Y-118.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.43%
OCF growth 3YN/A
OCF growth 5YN/A

SYNDAX PHARMACEUTICALS INC / SNDX FAQ

What is the fundamental rating for SNDX stock?

ChartMill assigns a fundamental rating of 3 / 10 to SNDX.


What is the valuation status for SNDX stock?

ChartMill assigns a valuation rating of 1 / 10 to SYNDAX PHARMACEUTICALS INC (SNDX). This can be considered as Overvalued.


Can you provide the profitability details for SYNDAX PHARMACEUTICALS INC?

SYNDAX PHARMACEUTICALS INC (SNDX) has a profitability rating of 1 / 10.


What is the financial health of SYNDAX PHARMACEUTICALS INC (SNDX) stock?

The financial health rating of SYNDAX PHARMACEUTICALS INC (SNDX) is 3 / 10.


Can you provide the expected EPS growth for SNDX stock?

The Earnings per Share (EPS) of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 14.45% in the next year.